| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
TA 0910 acid-type is a metabolite of TA-0910, which is a metabolically stable analogue of thyrotropin-releasing hormone (TRH). TRH is a tripeptide hormone that regulates the hypothalamic-pituitary-thyroid axis and has additional CNS effects. As a metabolite, TA 0910 acid-type may retain some of the biological activity of the parent compound.
|
|---|---|
| ln Vitro |
As a metabolite of TA-0910, TA 0910 acid-type is expected to exhibit similar biological activities to the parent compound, which include neuroprotective and CNS-stimulating effects. The specific in vitro activity of the acid-type metabolite is not extensively detailed in standard reference sources. TA-0910 itself is a TRH analog with enhanced metabolic stability.
|
| ln Vivo |
Specific in vivo activity data for TA 0910 acid-type are not extensively detailed in standard reference sources. As a metabolite of TA-0910, it may contribute to the overall pharmacological effects of the parent compound in vivo. TA-0910 has been studied in animal models for its neuroprotective and CNS effects.
|
| Enzyme Assay |
As a metabolite, TA 0910 acid-type can be used as a reference standard in analytical method development for the detection and quantification of TA-0910 and its metabolites in biological samples. Its chemical identity can be confirmed using HPLC, mass spectrometry, and NMR spectroscopy.
|
| Cell Assay |
TA 0910 acid-type can be used in cell-based assays to evaluate its biological activity and compare it to the parent compound TA-0910. Cells expressing TRH receptors can be treated with the metabolite, and downstream signaling (e.g., calcium mobilization, inositol phosphate production) can be measured. The metabolite's stability in cell culture media can also be assessed.
|
| Animal Protocol |
TA 0910 acid-type is typically used as a reference standard or analytical marker for pharmacokinetic and metabolism studies of TA-0910. In animal studies, TA-0910 is administered to rodents, and plasma and tissue samples are collected at various time points. The levels of TA-0910 and its metabolites, including TA 0910 acid-type, are measured using validated analytical methods (e.g., LC-MS/MS) to characterize the pharmacokinetic profile and metabolic pathways of the parent compound.
|
| ADME/Pharmacokinetics |
TA 0910 acid-type has a molecular formula of C17H22N6O6. Specific physicochemical properties such as solubility, logP, and pKa are not extensively detailed in standard reference sources. As a metabolite, it is typically studied in the context of pharmacokinetic and metabolic profiling of the parent compound TA-0910.
|
| Toxicity/Toxicokinetics |
The toxicity profile of TA 0910 acid-type is not extensively documented. As a metabolite of a TRH analog, it is expected to be present at low concentrations following administration of the parent compound. The safety profile of TA-0910 and its metabolites would be established through standard toxicological studies of the parent compound.
|
| Additional Infomation |
TA 0910 acid-type (CAS# 103300-77-2) is a metabolite of TA-0910, a metabolically stable analogue of thyrotropin-releasing hormone (TRH). It is used as a reference standard in analytical method development for pharmacokinetic studies of TA-0910. The compound is a research tool for studying TRH analog metabolism and pharmacology.
|
| Molecular Formula |
C17H22N6O6
|
|---|---|
| Molecular Weight |
406.39
|
| Exact Mass |
406.16
|
| CAS # |
103300-77-2
|
| PubChem CID |
128302
|
| Appearance |
White to off-white solid powder
|
| Density |
1.68g/cm3
|
| Index of Refraction |
1.743
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
29
|
| Complexity |
838
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C(O)(=O)[C@@H]1CCCN1C(=O)[C@H](C[C@@H]1NCNC1)NC(C1=CC(=O)N(C)C(=O)N1)=O
|
| Synonyms |
TA0910 acid-type; TA-0910 acid-type; TA 0910 acid-type
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~61.52 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4607 mL | 12.3035 mL | 24.6069 mL | |
| 5 mM | 0.4921 mL | 2.4607 mL | 4.9214 mL | |
| 10 mM | 0.2461 mL | 1.2303 mL | 2.4607 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
